45 results on '"Lucas, Judy"'
Search Results
2. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
3. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
4. Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
5. A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate
6. MOESM2 of Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
7. MCT4 is an important determinant for the growth of highly glycolytic and aggressive malignancies
8. PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
9. Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial
10. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
11. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate
12. Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
13. Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care
14. Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism
15. Abstract 2113: Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC
16. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
17. Abstract A2-33: Molecular profiling of patient-derived xenograft models across cancers
18. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
19. Abstract 1697: Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates
20. Abstract 5425: An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression
21. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH 2
22. Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
23. Abstract 4837: Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells
24. Abstract 2059: In situ imaging of antibody drug conjugate (ADC) binding and pharmacodynamic biomarkers of response in models of human cancer
25. Abstract 3487: CA9 expression highly correlates with cancer stem cell markers during passaging of PDX lines
26. Abstract 2669: Targeting the tumor vasculature with antibody drug conjugates
27. Abstract 5471: Notch-antibody drug conjugates have a different mechanism of action than Notch signaling inhibitors and induce tumor regression.
28. Abstract 4752: Preclinical development and translational research on a novel antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
29. Abstract 1241: Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer.
30. Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
31. MCT4 is an important determinant for the growth of highly glycolytic and aggressive malignancies
32. Abstract 2530: Long-term tumor regression induced by a novel antibody drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells
33. Abstract C117: Preclinical pharmacokinetics of an antibody-drug conjugate targeting 5T4.
34. Abstract A215: Antitumor activity of an antibody-drug conjugate targeting 5T4, a putative tumor-initiating cell antigen.
35. Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
36. Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
37. Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor
38. Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
39. Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
40. IκBα Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor α Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor Model
41. TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity
42. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines
43. SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
44. IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model.
45. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.